Correction to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with Avenzo

EAST BERLIN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced a correction to its press release issued November 10, 2026. The prior press release incorrectly stated that the one-for-two reverse stock split of Rallybio’s issued and outstanding common stock in connection with the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated as of May 31, 2026, among Rallybio, Avenzo Therapeutics, Inc. and Farmington Merger Sub, Inc. is expected